Evidence map›Paper›PMID 41842965›Full record

ArticleJCI insight2026

Safety of a tetravalent live dengue virus vaccine in children responding to one serotype only.

Laura J White, Lindsay D Hein, Maria Abad Fernandez, Cameron Adams, Elizabeth Adams, Emily Freeman, Ruby Shah, Lakshmanane Premkumar, Kristal An Agrupis, Maria Vinna Crisostomo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Laura J WhiteDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Lindsay D HeinDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Maria Abad FernandezDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Cameron AdamsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Elizabeth AdamsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Emily FreemanDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Ruby ShahDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.
Kristal An AgrupisInstitute of Child Health and Human Development, University of the Philippines Manila, Manila, Philippines.
Maria Vinna CrisostomoInstitute of Child Health and Human Development, University of the Philippines Manila, Manila, Philippines.
Jedas Veronica DaagInstitute of Child Health and Human Development, University of the Philippines Manila, Manila, Philippines.
Michelle YladeInstitute of Child Health and Human Development, University of the Philippines Manila, Manila, Philippines.
Jacqueline DeenInstitute of Child Health and Human Development, University of the Philippines Manila, Manila, Philippines.
Ana Lena LopezInstitute of Child Health and Human Development, University of the Philippines Manila, Manila, Philippines.
Leah KatzelnickViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Aravinda M de SilvaDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina, USA.

Funding

Project 5: mAb Development Flaviviruses and AlphavirusesU19AI181960 · NIAID · WASHINGTON UNIVERSITY · PI DIAMOND, MICHAEL S, KUHN, RICHARD J. · 2024 to 2024
$46.7M
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Daniela Weiskopf · 2015 to 2026
$34.1M
NIAID NIH HHS P01 AI106695NIAID NIH HHS U19 AI181960
6 · The paper itself

Abstract

Dengue virus (DENV) vaccines should be designed to induce balanced protective immunity to all 4 DENV serotypes to mitigate the risk of vaccine-enhanced dengue disease. The first tetravalent live DENV vaccine (Dengvaxia) tested in humans was efficacious in children who were partially immune to DENV at baseline. In DENV-naive children, the vaccine was not efficacious and placed some children at risk of more severe WT DENV breakthrough infections. To define dengue vaccine responses at the individual patient level and their relationship to mild and severe dengue infections, we prospectively studied a cohort of DENV-naive children who received 1 dose of Dengvaxia. The vaccine stimulated variable responses that neutralized 0, 1 (monotypic), or 2+ (multitypic) serotypes in individual children. Using a logistic regression model, we found that vaccinated children with neutralizing antibody (NAb) to 1 serotype only were at greater risk developing dengue compared with children who were not vaccinated (odds ratio 5.07). This risk was not observed in vaccinated children with no NAb or NAb to 2 or more serotypes. We propose that individuals with durable NAb to 1 serotype have an abundance of serotype cross-reactive, nonneutralizing antibodies implicated in the enhanced replication of heterologous serotypes.

Indexed as

Antibodies, NeutralizingAntibodies, ViralDengue VaccinesChildChild, PreschoolFemaleHumansMaleSerogroupVaccinationVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralDengue VaccinesVaccines, AttenuatedImmunologyInfectious diseaseVaccinesVirology

Identifiers

PMID41842965
PMCPMC13135402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.